Xceleron of the US and Crystal Pharmatech of Suzhou, China will partner to provide drug developers with their complimentary early-stage CRO services. Xceleron pioneered human microdose and microtracer accelerator mass spectrometry (AMS) technology, which clarifies the pharmacokinetics and metabolism of developmental drugs. Crystal Pharmatech applies material science principles to drug development, discovering the optimal solid phase for development. More details.... Share this with colleagues: // //